Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Net Asset Quality Index
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd net asset quality index. Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has a Net Asset Quality Index of 94.4% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.89 Billion minus total liabilities of CN¥161.98 Million yields net assets of CN¥2.73 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See what is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's book value for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
Net asset quality index of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024. This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 16 annual periods from 2009 to 2024. As of September 2025, the index stands at 94.4%, representing net assets of CN¥2.73 Billion against total assets of CN¥2.89 Billion CNY. Check Zhejiang Wolwo Bio-Pharmaceutical Co Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Net Asset Quality Index by Year (2009–2024)
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd net asset quality index by year from 2009 to 2024. The table below presents the year-by-year Net Asset Quality Index for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024, covering 16 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 300357 market cap overview.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 90.8% | CN¥2.46 Billion | CN¥2.71 Billion | CN¥250.30 Million | ▲ +0.8 pp |
| 2023 | 89.9% | CN¥2.30 Billion | CN¥2.56 Billion | CN¥258.46 Million | ▼ -2.3 pp |
| 2022 | 92.2% | CN¥2.03 Billion | CN¥2.20 Billion | CN¥170.76 Million | ▼ -0.8 pp |
| 2021 | 93.0% | CN¥1.80 Billion | CN¥1.93 Billion | CN¥135.36 Million | ▼ -2.2 pp |
| 2020 | 95.2% | CN¥1.53 Billion | CN¥1.60 Billion | CN¥76.61 Million | ▲ +0.6 pp |
| 2019 | 94.7% | CN¥1.35 Billion | CN¥1.43 Billion | CN¥76.25 Million | ▲ +0.6 pp |
| 2018 | 94.1% | CN¥995.42 Million | CN¥1.06 Billion | CN¥62.47 Million | ▼ -0.4 pp |
| 2017 | 94.5% | CN¥801.26 Million | CN¥848.31 Million | CN¥47.05 Million | ▲ +0.4 pp |
| 2016 | 94.1% | CN¥655.58 Million | CN¥696.89 Million | CN¥41.32 Million | ▼ -1.3 pp |
| 2015 | 95.3% | CN¥582.91 Million | CN¥611.49 Million | CN¥28.57 Million | ▼ -1.3 pp |
| 2014 | 96.7% | CN¥513.55 Million | CN¥531.31 Million | CN¥17.75 Million | ▲ +1.2 pp |
| 2013 | 95.4% | CN¥251.92 Million | CN¥263.95 Million | CN¥12.04 Million | ▲ +0.5 pp |
| 2012 | 94.9% | CN¥181.38 Million | CN¥191.11 Million | CN¥9.73 Million | ▲ +8.2 pp |
| 2011 | 86.7% | CN¥127.61 Million | CN¥147.19 Million | CN¥19.58 Million | ▲ +4.9 pp |
| 2010 | 81.8% | CN¥90.44 Million | CN¥110.52 Million | CN¥20.08 Million | ▼ -10.3 pp |
| 2009 | 92.2% | CN¥111.89 Million | CN¥121.38 Million | CN¥9.49 Million | — |